Senior Manager Biologics Drug Substance Process Development & Technology Transfer
AVEO Pharmaceuticals | |
United States, Massachusetts, Boston | |
30 Winter Street (Show on map) | |
Jul 21, 2026 | |
|
JOB TITLE: Senior Manager Biologics Drug Substance Process Development & Technology Transfer DEPARTMENT: Technical Operations/Biologics CMC REPORTS TO: Associate Director Biologics Drug Substance Development LOCATION: Boston MA DATE PREPARED: July 20, 2026 JOB SUMMARY: The Senior Manager, Biologics Drug Substance Process Development & Technology Transfer will lead drug substance process development, technology transfer, and manufacturing support for AVEO's biologics development portfolio. This highly visible role reports to the Associate Director of Biologics Drug Substance Development and provides technical oversight for early- and late-stage drug substance processes at AVEO's CMOs and CDMOs. The Senior Manager will oversee transfer of manufacturing processes from development into GMP manufacturing facilities and serve as the technical steward for biologics manufacturing processes from early-phase clinical manufacturing through process performance qualification (PPQ). The incumbent should hands-on experience in one or more drug substance disciplines of development or manufacturing areas. They will design phase appropriate studies that will ensure a robust GMP manufacturing process is able to be executed into the selected GMP manufacturing facility. Additionally, they will author and review protocols, development or GMP reports and executed batch records. In addition to technical competencies, this position will be required to work in a heavily matrixed organization across supply chain, quality, and regulatory functions to assure delivery of material for patients. They will also be an integral part of authoring and reviewing sections of regulatory documents including INDs, IMPDs and/or BLA dossiers. PRINCIPAL DUTIES:
About AVEO AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has several other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. | |
Jul 21, 2026